Individualized antimicrobial therapy using antibiotic combination testing and therapeutic drug monitoring to treat carbapenem-resistant Acintobacter baumannii infection

IF 4.9 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Antimicrobial Agents Pub Date : 2025-02-01 DOI:10.1016/j.ijantimicag.2024.107410

Nathalie Grace Sy Chua , Kelvin Kau-Kiat Goh , Tze Peng Lim , Sarah Silin Tang , Winnie Lee , Candice Yuen Yue Chan , Andrea Layhoon Kwa

{"title":"Individualized antimicrobial therapy using antibiotic combination testing and therapeutic drug monitoring to treat carbapenem-resistant Acintobacter baumannii infection","authors":"Nathalie Grace Sy Chua , Kelvin Kau-Kiat Goh , Tze Peng Lim , Sarah Silin Tang , Winnie Lee , Candice Yuen Yue Chan , Andrea Layhoon Kwa","doi":"10.1016/j.ijantimicag.2024.107410","DOIUrl":null,"url":null,"abstract":"<div><div>Treatment of multidrug resistant infections is challenging due to limited therapeutic options. To maximise treatment success of such infections, our infectious disease-trained pharmacists employ a two-pronged approach, using both <em>in vitro</em> antibiotic combination testing and therapeutic drug monitoring, to individualise antibiotic combination regimens for our patients, akin to precision medicine. This approach ensures that the most optimal antibiotic combination and dosing regimens are prescribed for our patients with multidrug resistant infection, to ensure adequate antibiotic exposure and maximal clinical efficacy. We describe the implementation of such 2-pronged approach in two of our patients infected with extensively drug-resistant <em>Acinetobacter baumannii</em> infections. Doses higher than manufacturer-approved regimens were administered. Both cases achieved treatment success with no adverse effects.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"65 2","pages":"Article 107410"},"PeriodicalIF":4.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Antimicrobial Agents","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924857924003261","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Treatment of multidrug resistant infections is challenging due to limited therapeutic options. To maximise treatment success of such infections, our infectious disease-trained pharmacists employ a two-pronged approach, using both in vitro antibiotic combination testing and therapeutic drug monitoring, to individualise antibiotic combination regimens for our patients, akin to precision medicine. This approach ensures that the most optimal antibiotic combination and dosing regimens are prescribed for our patients with multidrug resistant infection, to ensure adequate antibiotic exposure and maximal clinical efficacy. We describe the implementation of such 2-pronged approach in two of our patients infected with extensively drug-resistant Acinetobacter baumannii infections. Doses higher than manufacturer-approved regimens were administered. Both cases achieved treatment success with no adverse effects.

查看原文本刊更多论文

应用抗生素联合检测和治疗药物监测个体化抗菌治疗耐碳青霉烯鲍曼不动杆菌感染。

由于治疗选择有限，耐多药感染的治疗具有挑战性。为了最大限度地提高此类感染的治疗成功率，我们的传染病培训药剂师采用双管齐下的方法，使用体外抗生素组合测试和治疗药物监测，为我们的患者提供个性化的抗生素组合方案，类似于精准医学。这种方法确保为多重耐药感染患者开出最佳的抗生素组合和剂量方案，以确保充分的抗生素暴露和最大的临床疗效。我们描述了在我们的两名感染广泛耐药鲍曼不动杆菌感染的患者中实施这种双管齐下的方法。使用的剂量高于制造商批准的方案。两例均获得治疗成功，无不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Antimicrobial Agents 医学-传染病学

CiteScore

21.60

自引率

0.90%

发文量

176

审稿时长

36 days

期刊介绍： The International Journal of Antimicrobial Agents is a peer-reviewed publication offering comprehensive and current reference information on the physical, pharmacological, in vitro, and clinical properties of individual antimicrobial agents, covering antiviral, antiparasitic, antibacterial, and antifungal agents. The journal not only communicates new trends and developments through authoritative review articles but also addresses the critical issue of antimicrobial resistance, both in hospital and community settings. Published content includes solicited reviews by leading experts and high-quality original research papers in the specified fields.